CUA 2017: Immuno-Oncology Update in Advanced Bladder Cancer
Toronto, Ontario (UroToday.com) Dr. Kala Sridhar gave an all-encompassing presentation on the recent immunotherapy trials in advanced bladder cancer. Urothelial carcinoma (UC) the fifth most commonly diagnosed cancer, with 2300 deaths in Canada. Incidence rates are 3 times higher in men with an average age at diagnosis of 73.
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
Toronto, Ontario (UroToday.com) Dr. Kim Chi from the BC Cancer Agency delivered a high-level overview of the current landscape of urologic oncology immunotherapy at the State-of-the-Art Lecture at the 2017 CUA annual meeting. Since the interferon trials for metastatic kidney cancer in the 1990’s, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in melanoma and non-small cell lung cancer, followed by renal cell carcinoma (RCC).
CUA 2017: Update on Bladder Preservation in Muscle Invasive Disease
Toronto, Ontario (UroToday.com) Dr. Jason Efstathiou gave a talk on trimodal therapy (TMT) and bladder preservation in patients with muscle invasive bladder cancer (MIBC).
CUA 2017: PSMA-Targeted Radionuclide Therapies in Treatment of Prostate Cancer.
Toronto, Ontario (UroToday.com) Dr. Neil Fleshner gave a talk on PSMA targeted radionuclide therapies in prostate cancer (PC). Medical isotopes have historically been used to both image and treat cancer. Short lived radioisotopes are attached to molecules that specifically bind PSMA, and can detect PC using PET or SPECT. By attaching radioisotopes such Lutetium or Actinium, radioactivity is targeted to the PSMA-expressing cells.
CUA 2017: The Role of Testosterone Nadir Levels in Androgen Deprivation Therapy
Toronto, Ontario (UroToday.com) At the 5th Annual CUA-CUOG Multidisciplinary session at the 2017 CUA annual meeting, Dr. Robert Siemens from Queen’s University and Dr. Abdenour Nabid from Centre Hospitalier de Universitaire de Sherbrooke debated the role of testosterone nadir levels among men undergoing androgen deprivation therapy (ADT).
CUA 2017: Optimizing Active Surveillance for Prostate Cancer
Toronto, Ontario (UroToday.com) Dr. Stacy Loeb gave an excellent talk on the challenges and optimization of active surveillance (AS) in prostate cancer. Historically the vast majority of low risk patients received radical treatment, leading to unnecessary side effects. This has started to change, but even nowadays, in academic centers in the USA AS is utilized in 17% of cases, compared to 8% in community centers.
CUA 2017: Role of MRI in Diagnosing Prostate Cancer
Toronto, Ontario (UroToday.com) Dr. Sangeet Ghai, a uro-radiologist at Princess Margaret Cancer Centre (PMCC), provided an overview of the role of MRI in the diagnosis of prostate cancer, focusing on patients with a prior negative biopsy and men on AS, but foraying into the biopsy-naïve segment as well.